Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC11 | Q96DB2 | 12/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.66 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | HCN1 | O60741 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20096742 | 0.88 | HDAC11 (0.79) | HDAC11HDAC6HDAC3HDAC1HDAC2 | |
| SCHEMBL20096482 | 0.86 | HDAC11 (1.00) | HDAC11HDAC6HDAC3HDAC1HDAC2 | |
| SCHEMBL20132889 | 0.86 | HDAC11 (0.76) | HDAC11HDAC6HDAC1 | |
| SCHEMBL20096475 | 0.85 | HDAC11 (0.77) | HDAC11HDAC6 | |
| SCHEMBL20096917 | 0.83 | HDAC11 (0.72) | HDAC11HDAC6 | |
| SCHEMBL20096914 | 0.83 | HDAC11 (0.75) | HDAC11HDAC6HDAC3HDAC1HDAC2 | |
| SCHEMBL20096474 | 0.83 | HDAC11 (0.82) | HDAC11HDAC6 | |
| SCHEMBL20096912 | 0.83 | HDAC11 (0.86) | HDAC11HDAC6 | |
| SCHEMBL20096739 | 0.82 | HDAC11 (0.73) | HDAC11HDAC6HDAC3HDAC1HDAC2 | |
| SCHEMBL20096849 | 0.82 | HDAC11 (0.78) | HDAC11HDAC6HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345672-B2 | Methods using HDAC11 inhibitors | VALO HEALTH, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20190084946-A1 | METHODS USING HDAC11 INHIBITORS | Valo Health, LLC | 2019-03-21 | — | — | US | disclosed |
| US-20190084945-A1 | METHODS USING HDAC11 INHIBITORS | VALO HEALTH, INC. | 2019-03-21 | — | — | US | disclosed |
| US-20180127386-A1 | METHODS USING HDAC11 INHIBITORS | VALO EARLY DISCOVERY, INC. | 2018-05-10 | — | — | US | disclosed |
| WO-2018075959-A1 | METHODS USING HDAC11 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345672-B2 | Methods using HDAC11 inhibitors | HDAC11, HDAC1, HDAC10 | HDAC11 1/4885HDAC6 6/4885HDAC3 7/4885 |
| US-20180127386-A1 | METHODS USING HDAC11 INHIBITORS | HDAC11, HDAC1, HDAC10 | HDAC11 1/4885HDAC6 6/4885HDAC3 7/4885 |
| US-20190084945-A1 | METHODS USING HDAC11 INHIBITORS | HDAC11, HDAC1, HDAC10 | HDAC11 1/4885HDAC6 6/4885HDAC3 7/4885 |
| US-20190084946-A1 | METHODS USING HDAC11 INHIBITORS | HDAC11, HDAC1, HDAC10 | HDAC11 1/4885HDAC6 6/4885HDAC3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.